Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes

Not Applicable

Recruiting

• Conditions: Robotic-Assisted Radical Prostatectomy; Locally Advanced Prostate Cancer; Bladder Suspension

• Registration Number: NCT06977906
• Lead Sponsor: First Affiliated Hospital of Fujian Medical University

Brief Summary

This study is a prospective, single-center clinical trial. It aims to establish an improved robotic-assisted radical prostatectomy for treating locally advanced prostate cancer. The technique evaluates the impact of preserving the anterior peritoneum of the bladder on postoperative bladder descent and urinary control recovery. A retrospective analysis compares this modified approach with traditional anterior approach surgery, assessing differences in oncological outcomes, early functional recovery, and postoperative complication rates. The goal is to provide new theoretical foundations and technical support for the prevention and treatment of postoperative urinary incontinence.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-01-01
• Status Verified: 2025-05
• Study First Submitted: 2025-05-12
• Study First Submitted QC: 2025-05-12
• Last Update Submitted: 2025-05-12
• Study First Posted: 2025-05-18
• Last Update Posted: 2025-05-18
• Primary Completion: 2027-01-01
• Study Completion: 2027-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 300

Inclusion Criteria

1. prostate biopsy and clinical confirmation of high-risk prostate cancer (PSA > 20 ng/mL, Gleason score ≥ 8, or cT stage ≥ T2c) followed by robotic-assisted radical prostatectomy
2. multiparametric MRI (mpMRI) with a 3.0 T scanner for prostate or pelvic scans performed within 30 days before the operation at our center
3. Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1
4. Complete clinical and prostate biopsy pathological data.
5. General health is good, with no infections, autoimmune diseases, hematologic disorders, or other malignancies.

Exclusion Criteria

1. Presence of surgical contraindications.
2. refusal of enhanced mpMRI imaging.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
rate of continence	1 week, 1 month and 3 month after postoperative removal of the urinary catheter	Time Frame:1 week, 1 month and 3 month after postoperative removal of the urinary catheter
The degree of bladder descent	1 month after operation	Time Frame:1 month after operation

Trial Locations

Locations (1)

first hospital affiliated of Fujian medical university; 🇨🇳 Fuzhou, Fujian, China